The Other Side of Possible…

What does OSOP mean to us?

Unwavering Commitment
to Science and Patients

Learn About
Our Research Platform

What Drives Us?

The many friends and family of Agios employees affected by cancer are what motivates, inspires and drives us.

Melissa McLaughlin
SVP Human Resources

Our Research Focus

Cancer Metabolism

Inhibit key enzymes in cancer cell specific metabolic pathways to disrupt tumor cell proliferation and survival

Rare Genetic Diseases

Restore defective metabolic pathways in disease cells that cause rare genetic disorders of metabolism

Metabolic
Immuno-Oncology

Alter the metabolic state of immune cells to enhance the body’s anti-tumor response

Boldly Pursuing Excellence and Innovation

We are a research-driven organization focused on creating transformative medicines by combining expertise in metabolism and precision medicine.

research platform

The Spirit of Agios

The Spirit of Agios

At Agios, our culture and values are embodied in the Greek word Arete, the ancient ideal of excellence and fulfillment of one’s potential to which our employees aspire. Together, we are driven by a boundless passion for our work, and we pride ourselves on fostering an interconnected environment that encourages creative scientific collaboration across disciplines.

explore agios’ culture explore agios’ values

Passion for Discovery

our pipeline

Agios has leveraged its core capabilities in cellular metabolism and precision medicine to build a product engine that is focused in the therapeutic areas of cancer and rare genetic diseases.

CANDIDATE
Early Stage Clinical Development
Late Stage Development
APPROVED
R/R AML
Phase 3
Frontline AML
Phase 1b 7+3 Combo
Frontline AML
Phase 1/2 VIDAZA® Combo
  • Celgene has worldwide development and commercialization rights.Agios has U.S. co –promotion and royalty rights.
Frontline AML
Phase 3
R/R AML
Phase 1 Dose Escalation
Expansion Cohorts
Frontline AML
Phase 1b 7+3 Combo
Frontline AML
Phase 1/2 VIDAZA® Combo
Solid Tumors
Phase 1 Dose Escalation
Expansion Cohorts
Cholangiocarcinoma
Phase 3
Solid Tumors
Phase 1 Dose Escalation

Joint worldwide collaboration with Celgene.   

The safety and efficacy of the agents and uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

Recent News & Events

11/17/2017

Agios Presents Updated Phase 1 Data from Dose Expansion Cohort of Ivosidenib (AG-120) in Patients with IDH1 Mutant Positive Glioma
read more

11/01/2017

Agios to Present New Data from PKR and IDH Programs at the 2017 ASH Annual Meeting
read more

11/01/2017

Agios Reports Third Quarter 2017 Financial Results
read more

10/31/2017

Agios to Present at the 26th Annual Credit Suisse Healthcare Conference Tuesday, November 7, 2017
read more

Agios has a dynamic culture that supports our employees’ unwavering commitment to science and patients.

career opportunities